Last updated: August 9, 2026
Drospirenone and ethinyl estradiol is a mature oral contraceptive combination with substantial historical sales but limited current branded pricing power. The market shifted from Bayer’s Yasmin and Yaz franchises to generic products after U.S. patent and regulatory exclusivity periods ended. Current commercial value is distributed across multiple generic suppliers, while Bayer retains limited branded exposure through products such as Yaz and Beyaz in selected markets. Public companies generally do not report revenue for the combination separately, making market-volume data more reliable than product-level financial data.
What is drospirenone and ethinyl estradiol?
Drospirenone and ethinyl estradiol is a combined oral contraceptive containing the progestin drospirenone and the estrogen ethinyl estradiol. The principal dosage strengths are:
| Product type |
Drospirenone |
Ethinyl estradiol |
Main commercial use |
| Yasmin-type |
3 mg |
0.03 mg |
Pregnancy prevention |
| Yaz-type |
3 mg |
0.02 mg |
Pregnancy prevention; some products include PMDD and acne indications |
| Beyaz-type |
3 mg |
0.02 mg |
Contraception, PMDD, acne, and folate supplementation |
| Generic equivalents |
3 mg |
0.02 or 0.03 mg |
Substitution for branded products |
Yasmin contains 3 mg of drospirenone and 0.03 mg of ethinyl estradiol. Yaz contains 3 mg of drospirenone and 0.02 mg of ethinyl estradiol. Beyaz adds levomefolate calcium to the Yaz formulation. The U.S. Food and Drug Administration approved Yasmin in 2001 and Yaz in 2006.[1][2]
Drospirenone has antimineralocorticoid and antiandrogenic properties. Those characteristics helped differentiate the product from older oral contraceptives based on levonorgestrel or norethindrone, although they also generated safety scrutiny concerning venous thromboembolism and hyperkalemia.
How large is the drospirenone and ethinyl estradiol market?
The market is large in prescription volume but fragmented in revenue. Branded products achieved peak sales before generic entry, while current revenue is spread among generic manufacturers, private-label suppliers, wholesalers, and regional brands.
The main market segments are:
- Standard combined oral contraceptive prescriptions.
- Extended-cycle and low-dose formulations.
- Products marketed for premenstrual dysphoric disorder.
- Products marketed for acne treatment.
- Folate-containing products such as Beyaz.
- Generic equivalents supplied through retail, mail-order, Medicaid, and managed-care channels.
The United States remains commercially important because of its high prescription volume and structured generic substitution system. Europe and Latin America have broader brand and country-specific generic competition. The combination is also sold under different brand names, strengths, and regulatory classifications across jurisdictions.
No single company reports global revenue for all drospirenone and ethinyl estradiol products. Bayer reports women’s healthcare results at a portfolio level rather than disclosing current revenue for Yasmin, Yaz, or Beyaz as individual products.[3]
What was the financial trajectory of Yasmin and Yaz?
Bayer’s drospirenone franchise followed a conventional pharmaceutical lifecycle:
| Period |
Commercial phase |
Financial effect |
| 2001-2005 |
Yasmin launch and geographic expansion |
Rapid branded growth |
| 2006-2009 |
Yaz launch and portfolio expansion |
Higher revenue through new strength and indications |
| 2010-2012 |
Mature branded franchise |
High sales but increasing safety and litigation costs |
| 2013-2016 |
Generic erosion in major markets |
Sharp decline in branded revenue |
| 2017-present |
Mature generic market |
Low branded contribution and fragmented supplier revenue |
Yasmin became one of Bayer’s major women’s healthcare products. Yaz extended the franchise with a lower ethinyl estradiol dose and additional approved uses in certain jurisdictions. Bayer’s combined oral contraceptive franchise reached approximately billion-euro annual sales at its peak, although public filings did not consistently isolate drospirenone and ethinyl estradiol revenue from the broader women’s healthcare portfolio.[3]
The financial decline began when generic versions entered the U.S. market and European markets. Oral contraceptives have limited technical barriers to generic manufacturing once the active ingredients, dissolution profile, impurities, and bioequivalence requirements are established. The result was rapid price compression and loss of branded prescription share.
Current branded sales are unlikely to resemble the peak Yasmin and Yaz years. The product’s economic value is now primarily associated with manufacturing scale, contracting access, formulation differentiation, and regional distribution rather than strong patent-based pricing.
When did drospirenone and ethinyl estradiol lose exclusivity?
The combination lost practical exclusivity in stages rather than on a single global date.
United States exclusivity
Yasmin and Yaz were protected by a combination of patents, regulatory exclusivity, pediatric extensions, formulation claims, and litigation settlements. Generic entry occurred after the principal patent barriers were resolved or became commercially ineffective.
Key milestones included:
| Milestone |
Approximate timing |
Market impact |
| Yasmin FDA approval |
2001 |
Branded market established |
| Yaz FDA approval |
2006 |
Lower-dose franchise expanded |
| First U.S. generic approvals |
Late 2000s to early 2010s |
Price and share erosion began |
| Multiple generic suppliers |
2011 onward |
Rapid commoditization |
| Mature generic market |
Mid-2010s onward |
Low average selling prices |
The exact loss-of-exclusivity date differs by product, dosage strength, patent listing, pediatric extension, and settlement terms. The FDA Orange Book must be reviewed by individual NDA and strength because Yasmin, Yaz, and Beyaz do not have identical listing profiles.[4]
What patents protect drospirenone and ethinyl estradiol?
The historical patent estate covered the active combination, pharmaceutical compositions, dosing regimens, and selected treatment uses. The strongest commercial patents were associated with Bayer’s original drospirenone development program and later Yaz-related formulations.
Core patent categories
| Patent category |
Protected subject matter |
Current commercial strength |
| Active combination patents |
Drospirenone plus ethinyl estradiol |
Mostly expired or commercially weak |
| Formulation patents |
Tablet composition, excipients, dissolution, stability |
Limited protection unless tied to a differentiated product |
| Method-of-use patents |
PMDD, acne, contraception, symptom treatment |
Relevant only to labeled or enforceable uses |
| Folate combination patents |
Drospirenone, ethinyl estradiol, and levomefolate |
Narrower market protection |
| Manufacturing patents |
Synthesis, purification, particle properties |
Potentially relevant to supply chains |
| Regulatory exclusivity |
New drug and pediatric exclusivity |
Expired for the principal products |
The original patent estate was more valuable during the branded period than it is today. Most relevant U.S. patents for the original products have expired or no longer prevent generic competition. Remaining rights, where applicable, are more likely to affect specific formulations, manufacturing processes, or narrow methods of use than the entire generic market.
A patent-number analysis must distinguish patents listed for the NDA from patents assigned to related drospirenone products. Slynd, the drospirenone-only contraceptive, has a separate patent and exclusivity profile and should not be included in a direct patent analysis of drospirenone and ethinyl estradiol.[4][5]
What is the Orange Book status of Yaz, Yasmin, and Beyaz?
The Orange Book provides the operative U.S. reference for listed patents, therapeutic equivalence codes, and approved reference products. Yaz, Yasmin, and Beyaz are approved prescription products with generic equivalents or potential generic equivalents depending on strength and formulation.
The principal regulatory distinction is:
- Generic products referencing Yaz generally contain 3 mg drospirenone and 0.02 mg ethinyl estradiol.
- Generic products referencing Yasmin generally contain 3 mg drospirenone and 0.03 mg ethinyl estradiol.
- Beyaz-equivalent products must address the levomefolate component and the relevant formulation requirements.
FDA-approved generic products may receive AB therapeutic-equivalence ratings where they meet the agency’s requirements for pharmaceutical equivalence and bioequivalence. Substitution rules remain subject to state law, payer policy, and pharmacy practice.[4]
Which companies compete in the generic market?
Competition includes large generic manufacturers, specialty suppliers, and regional firms. Companies that have marketed or supplied drospirenone and ethinyl estradiol products in the United States include:
- Teva Pharmaceuticals
- Glenmark Pharmaceuticals
- Lupin Pharmaceuticals
- Mylan, now part of Viatris
- Prasco Laboratories
- Zydus Pharmaceuticals
- Dr. Reddy’s Laboratories
- Amneal Pharmaceuticals
- Xiromed and other authorized or private-label suppliers
The commercial leader can change by dosage strength, payer contract, product availability, and manufacturing status. A supplier with an approved ANDA may not maintain continuous commercial distribution. Shortages, recalls, facility constraints, and raw-material availability can alter market share quickly.
Bayer remains the originator associated with Yasmin, Yaz, and Beyaz, but the economic structure has changed. The originator’s principal advantages are brand recognition, regulatory history, safety monitoring, and physician familiarity. Generic suppliers compete primarily on cost, supply reliability, wholesaler access, and payer coverage.
Which companies challenged the patents, and what litigation affected the market?
Generic entry followed abbreviated new drug applications and patent certifications, including Paragraph IV challenges where applicants alleged that listed patents were invalid, unenforceable, or not infringed.
Litigation involving drospirenone and ethinyl estradiol products focused on:
- Validity of formulation and composition claims.
- Infringement by generic tablet formulations.
- Patent term and pediatric extensions.
- Settlement timing and authorized generic arrangements.
- Product labeling for PMDD and acne indications.
- Safety-related consumer and state enforcement claims.
The most commercially important litigation was the patent litigation that determined the timing of generic Yaz and Yasmin entry. Once multiple generic products obtained approval and launched, subsequent litigation had limited ability to restore broad market exclusivity.
Safety litigation involving drospirenone-containing contraceptives also affected marketing costs and risk perception. Claims generally concerned thromboembolic risk and whether product communications adequately described comparative safety issues. Those cases were separate from patent disputes but affected the franchise’s financial trajectory through legal expense, settlements, and reputational pressure.[3][6]
What formulation and method-of-use patents remain relevant?
Formulation patents have greater potential value than basic combination patents only where they protect a product that is difficult to substitute with a standard generic. Examples include:
- Specific low-dose estrogen compositions.
- Tablets containing drospirenone with levomefolate.
- Controlled-release or extended-cycle delivery.
- Stability improvements.
- Particle-size or polymorph limitations.
- Manufacturing processes that reduce impurities.
- Packaging systems designed to protect stability.
Method-of-use patents can cover PMDD, acne, or contraceptive regimens. Their commercial effect depends on the product label, the scope of the claims, and whether generic labeling omits protected uses. Skinny-label strategies may reduce infringement exposure for generic manufacturers, although the analysis depends on the specific claims and prescribing behavior.
The residual patent strength of the original Yasmin and Yaz estate is low for ordinary generic contraception. Narrow formulation and process claims may retain value, but they do not recreate the broad exclusivity once associated with the branded products.
What FDA regulatory issues affect the market?
The FDA requires generic manufacturers to demonstrate pharmaceutical equivalence and bioequivalence. The combination presents regulatory issues involving:
- Drospirenone assay and content uniformity.
- Dissolution performance for both active ingredients.
- Impurity controls.
- Stability and shelf life.
- Bioequivalence under the applicable product-specific guidance.
- Labeling for contraindications and warnings.
- Potassium-related warnings associated with drospirenone’s antimineralocorticoid activity.
The approval pathway is generally an ANDA for a generic equivalent to an approved reference listed drug. A 505(b)(2) application may be relevant for a modified formulation or a product that relies partly on published or previously established data, although the commercial opportunity depends on the degree of differentiation.
What generic entry risks exist for drospirenone and ethinyl estradiol?
Generic entry risk is high because:
- The main products are old and widely characterized.
- The active ingredients are chemically defined.
- The dosage forms are conventional oral tablets.
- Multiple suppliers can manufacture the products.
- Prescribers and payers have established substitution practices.
- Most broad patent barriers have expired.
- Demand is recurrent but price-sensitive.
The primary remaining risks are operational rather than patent-based. These include manufacturing interruptions, FDA warning letters, product recalls, quality failures, supplier concentration, and shortages. A company with a differentiated folate formulation or a reliable low-cost manufacturing platform may preserve margins, but ordinary generic products generally face sustained price pressure.
How does drospirenone and ethinyl estradiol compare with Slynd?
Slynd contains drospirenone without ethinyl estradiol. It is a progestin-only oral contraceptive and has a different regulatory, patent, and commercial profile.
| Attribute |
Drospirenone/ethinyl estradiol |
Slynd |
| Estrogen component |
Present |
Absent |
| Main products |
Yasmin, Yaz, Beyaz, generics |
Slynd |
| Market maturity |
Mature generic market |
Newer branded lifecycle |
| Patent risk |
Generally low for core combination |
Higher, depending on listed patents |
| Differentiation |
Dose, indications, folate, brand |
Estrogen-free regimen and dosing schedule |
| Revenue model |
Generic volume and low prices |
Branded pricing and exclusivity |
The two products should not be treated as interchangeable commercial assets. Slynd may retain higher branded value because it addresses patients seeking an estrogen-free oral contraceptive and has a more recent commercial launch history.[5]
What is the future financial trajectory?
The financial trajectory for drospirenone and ethinyl estradiol is likely to remain mature and volume-driven.
Base-case market outlook
Revenue should remain concentrated in:
- Generic prescription volume.
- Low-cost manufacturing.
- Payer and pharmacy contracts.
- Regional brand retention.
- Product extensions such as folate-containing tablets.
- Markets where generic penetration remains incomplete.
Branded revenue is likely to continue declining or remain modest unless a company obtains meaningful differentiation through a new delivery system, improved safety profile, digital adherence program, or regulatory approval for a distinct patient population.
The combination is unlikely to regain its historical blockbuster economics. Its commercial value is durable because contraception demand is recurring, but the product is no longer protected by broad, enforceable exclusivity in the principal U.S. market.
Key Takeaways
- Drospirenone and ethinyl estradiol is a mature combined oral contraceptive market.
- Yasmin and Yaz generated substantial branded revenue before generic entry.
- Generic competition has reduced prices and fragmented market share.
- Bayer’s current public reporting does not isolate revenue for the individual products.
- Broad composition and combination protection is largely expired or commercially ineffective.
- Remaining value is concentrated in manufacturing efficiency, supply reliability, narrow formulations, and selected method-of-use claims.
- FDA Orange Book analysis must be conducted separately for Yasmin, Yaz, and Beyaz.
- Generic entry risk is high, while operational and quality risks are more important than core patent risk.
- Slynd is a separate drospirenone-only product with a different patent and commercial profile.
- The future market is likely to produce stable prescription volume but limited pricing growth.
FAQs
What is the difference between Yaz and Yasmin?
Yaz contains 3 mg of drospirenone and 0.02 mg of ethinyl estradiol. Yasmin contains 3 mg of drospirenone and 0.03 mg of ethinyl estradiol. The products also have different approved indications and generic reference products.
Is drospirenone and ethinyl estradiol still a profitable drug?
It remains commercially viable for efficient generic manufacturers, but ordinary products have limited margins because of intense competition and payer substitution. The original branded-level profitability has largely disappeared.
Does Beyaz have separate patent protection from Yaz?
Beyaz contains levomefolate in addition to the Yaz active ingredients. Its formulation, labeling, and patent analysis therefore differs from the analysis for a standard drospirenone and ethinyl estradiol product.
Are generic Yaz and generic Yasmin interchangeable?
No. The products have different ethinyl estradiol strengths. A generic referencing Yaz is not automatically therapeutically equivalent to a generic referencing Yasmin.
Can a new company still obtain FDA approval for this combination?
Yes. A company may pursue an ANDA for a qualifying generic product or a 505(b)(2) pathway for a differentiated formulation. Commercial success depends on reference-product eligibility, patent certifications, bioequivalence, manufacturing capacity, and payer access.
References
- U.S. Food and Drug Administration. (2001). Yasmin prescribing information.
- U.S. Food and Drug Administration. (2006). Yaz prescribing information.
- Bayer AG. (Various years). Annual reports and financial statements.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Slynd prescribing information.
- U.S. Food and Drug Administration. (2024). Drug safety communication: Drospirenone-containing oral contraceptives and thromboembolic risk.
